TOM and REM
In recent years hardly any other area of medicine has experienced such a gain in knowledge as cell biology.
With increasing understanding of cellular processes, researchers are now able to more intensively pursue the goal of using human cells as tools for the therapy of a broad range of diseases.
Our health depends decisively upon having a balanced immune system. The absence of or excessive immune responses can hinder successful therapy and lead to chronic inflammatory reactions or diseases of the autoimmune system. In this connection Professor Fändrich of the University of Kiel has developed two cell products from monocytic cells of the immune system in order to restore this balance.
So-called tolerogenic macrophages, known in short form as TOM, have been found to successfully alleviate excessive immune responses by B- and T-cells, for example dermatosclerosis, vasculitis such as Wegner's disease, Sjörgren syndrome, lupus erythematosus, diabetes mellitus, and ulcerative colitis in clinical therapy testing and for tolerance reduction following live allogenous kidney transplants.
Regenerative macrophages are characterised by their anti-inflammatory effect and their high morphological plasticity. Due to the release of growth factors they can promote the formation of new vessels. This property has already been successfully tested with coronary hypoperfusion and in patients with arterial occlusions in Stage III and IV. Furthermore, they find clinical use for the therapy of different neuro-degenerative diseases, such as Parkinson's disease, amyotrophic lateral sclerosis, and Alzheimer's disease.